$27.62
-0.57 (-2.02%)
Performance
1D
—
1W
—
1M
—
3M
—
6M
+30.71%
1Y
+197.63%
YTD
+18.59%
Open$27.76
Previous Close$28.19
Day High$28.15
Day Low$27.02
52W High$31.74
52W Low$8.84
Volume—
Avg Volume1.10M
Market Cap3.53B
P/E Ratio—
EPS$-3.18
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$22.13
Above
SMA 200
$15.14
Above
RSI (14)
36.6
Neutral
Trend
Golden Cross
Bullish
Analyst Ratings
Strong Buy
19 analysts
Price Target
+263.9% upside
Current
$27.62
$27.62
Target
$100.50
$100.50
$77.00
$100.50 avg
$121.27
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 286.05M | 219.77M | 841.86M |
| Net Income | -408,809,304 | -282,673,919 | -67,570,170 |
| Profit Margin | -142.9% | -135.8% | -8.0% |
| EBITDA | -435,438,874 | -317,814,175 | -58,220,570 |
| Free Cash Flow | — | — | -41,442,789 |
| Rev Growth | +30.2% | +30.2% | +8.2% |
| Debt/Equity | 0.16 | 0.16 | 0.24 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $245.22 | +0.55% | 122.9 | 446.67B |
| AMGN | Amgen Inc | $407.95 | +0.77% | 26.5 | 206.48B |
| GILD | Gilead Sciences Inc | $133.75 | +2.21% | 17.6 | 161.72B |
| VRTX | Vertex Pharmaceuticals Inc | $484.53 | -0.06% | 27.8 | 120.52B |
| REGN | Regeneron Pharmaceuticals | $782.10 | +1.29% | 17.5 | 77.36B |
| ALNY | Alnylam Pharmaceuticals Inc | $217.68 | +0.72% | 47.7 | 27.52B |